Researchers identified a cytokine called interleukin-1 that contributes to the progression of myelofibrosis. Targeting this cytokine can prevent myelofibrosis and spare bone marrow from the scarring that is a hallmark of the disease.
The discovery not only provides a new treatment approach, but sheds light on the fundamental mechanisms of progression of myeloproliferative neoplasms, according to a Nov. 9 UVA release.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.